174 related articles for article (PubMed ID: 29317678)
1. Peptidomimetic blockade of MYB in acute myeloid leukemia.
Ramaswamy K; Forbes L; Minuesa G; Gindin T; Brown F; Kharas MG; Krivtsov AV; Armstrong SA; Still E; de Stanchina E; Knoechel B; Koche R; Kentsis A
Nat Commun; 2018 Jan; 9(1):110. PubMed ID: 29317678
[TBL] [Abstract][Full Text] [Related]
2. The natural anti-tumor compound Celastrol targets a Myb-C/EBPβ-p300 transcriptional module implicated in myeloid gene expression.
Coulibaly A; Haas A; Steinmann S; Jakobs A; Schmidt TJ; Klempnauer KH
PLoS One; 2018; 13(2):e0190934. PubMed ID: 29394256
[TBL] [Abstract][Full Text] [Related]
3. A Dual-Site Inhibitor of CBP/p300 KIX is a Selective and Effective Modulator of Myb.
Joy ST; Henley MJ; De Salle SN; Beyersdorf MS; Vock IW; Huldin AJL; Mapp AK
J Am Chem Soc; 2021 Sep; 143(37):15056-15062. PubMed ID: 34491719
[TBL] [Abstract][Full Text] [Related]
4. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
Jiang Y; Gao R; Cao C; Forbes L; Li J; Freeberg S; Fredenburg KM; Justice JM; Silver NL; Wu L; Varma S; West R; Licht JD; Zajac-Kaye M; Kentsis A; Kaye FJ
Oral Oncol; 2019 Nov; 98():147-155. PubMed ID: 31606723
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a Promising CBP/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia.
Wu T; Hu J; Zhao X; Zhang C; Dong R; Hu Q; Xu H; Shen H; Zhang X; Zhang Y; Lin B; Wu X; Xiang Q; Xu Y
J Med Chem; 2024 Jun; 67(11):9194-9213. PubMed ID: 38829718
[TBL] [Abstract][Full Text] [Related]
6. Conformational control of the binding of the transactivation domain of the MLL protein and c-Myb to the KIX domain of CREB.
Korkmaz EN; Nussinov R; Haliloğlu T
PLoS Comput Biol; 2012; 8(3):e1002420. PubMed ID: 22438798
[TBL] [Abstract][Full Text] [Related]
7. Discovery of Highly Potent and Efficient CBP/p300 Degraders with Strong
Hu J; Xu H; Wu T; Zhang C; Shen H; Dong R; Hu Q; Xiang Q; Chai S; Luo G; Chen X; Huang Y; Zhao X; Peng C; Wu X; Lin B; Zhang Y; Xu Y
J Med Chem; 2024 May; 67(9):6952-6986. PubMed ID: 38649304
[TBL] [Abstract][Full Text] [Related]
8. Generation of a Selective Small Molecule Inhibitor of the CBP/p300 Bromodomain for Leukemia Therapy.
Picaud S; Fedorov O; Thanasopoulou A; Leonards K; Jones K; Meier J; Olzscha H; Monteiro O; Martin S; Philpott M; Tumber A; Filippakopoulos P; Yapp C; Wells C; Che KH; Bannister A; Robson S; Kumar U; Parr N; Lee K; Lugo D; Jeffrey P; Taylor S; Vecellio ML; Bountra C; Brennan PE; O'Mahony A; Velichko S; Müller S; Hay D; Daniels DL; Urh M; La Thangue NB; Kouzarides T; Prinjha R; Schwaller J; Knapp S
Cancer Res; 2015 Dec; 75(23):5106-5119. PubMed ID: 26552700
[TBL] [Abstract][Full Text] [Related]
9. Reversal of MYB-dependent suppression of MAFB expression overrides leukaemia phenotype in MLL-rearranged AML.
Negri A; Ward C; Bucci A; D'Angelo G; Cauchy P; Radesco A; Ventura AB; Walton DS; Clarke M; Mandriani B; Pappagallo SA; Mondelli P; Liao K; Gargano G; Zaccaria GM; Viggiano L; Lasorsa FM; Ahmed A; Di Molfetta D; Fiermonte G; Cives M; Guarini A; Vegliante MC; Ciavarella S; Frampton J; Volpe G
Cell Death Dis; 2023 Nov; 14(11):763. PubMed ID: 37996430
[TBL] [Abstract][Full Text] [Related]
10. C/EBPβ cooperates with MYB to maintain the oncogenic program of AML cells.
Klempnauer KH
Oncotarget; 2023 Mar; 14():174-177. PubMed ID: 36913305
[TBL] [Abstract][Full Text] [Related]
11. Transcription Factor MYB as Therapeutic Target: Current Developments.
Klempnauer KH
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542205
[TBL] [Abstract][Full Text] [Related]
12. Acquired immune resistance is associated with interferon signature and modulation of KLF6/c-MYB transcription factors in myeloid leukemia.
Parveen M; Karaosmanoglu B; Sucularli C; Uner A; Taskiran EZ; Esendagli G
Eur J Immunol; 2024 May; 54(5):e2350717. PubMed ID: 38462943
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent and selective CBP bromodomain inhibitor (Y08262) for treating acute myeloid leukemia.
Xiang Q; Wu T; Zhang C; Wang C; Xu H; Hu Q; Hu J; Luo G; Zhuang X; Wu X; Zhang Y; Xu Y
Bioorg Chem; 2024 Jan; 142():106950. PubMed ID: 37924753
[TBL] [Abstract][Full Text] [Related]
14.
Almeida A; T'Sas S; Pagliaro L; Fijalkowski I; Sleeckx W; Van Steenberge H; Zamponi R; Lintermans B; Van Loocke W; Palhais B; Reekmans A; Bardelli V; Demoen L; Reunes L; Deforce D; Van Nieuwerburgh F; Kentsis A; Ntziachristos P; Van Roy N; De Moerloose B; Mecucci C; La Starza R; Roti G; Goossens S; Van Vlierberghe P; Pieters T
Hemasphere; 2024 Mar; 8(3):e51. PubMed ID: 38463444
[TBL] [Abstract][Full Text] [Related]
15. The ETO2 transcriptional cofactor maintains acute leukemia by driving a MYB/EP300-dependent stemness program.
Fagnan A; Aid Z; Baille M; Drakul A; Robert E; Lopez CK; Thirant C; Lecluse Y; Rivière J; Ignacimouttou C; Salmoiraghi S; Anguita E; Naimo A; Marzac C; Pflumio F; Malinge S; Wichmann C; Huang Y; Lobry C; Chaumeil J; Soler E; Bourquin JP; Nerlov C; Bernard OA; Schwaller J; Mercher T
Hemasphere; 2024 Jun; 8(6):e90. PubMed ID: 38903535
[TBL] [Abstract][Full Text] [Related]
16. MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.
Brown FC; Still E; Koche RP; Yim CY; Takao S; Cifani P; Reed C; Gunasekera S; Ficarro SB; Romanienko P; Mark W; McCarthy C; de Stanchina E; Gonen M; Seshan V; Bhola P; O'Donnell C; Spitzer B; Stutzke C; Lavallée VP; Hébert J; Krivtsov AV; Melnick A; Paietta EM; Tallman MS; Letai A; Sauvageau G; Pouliot G; Levine R; Marto JA; Armstrong SA; Kentsis A
Cancer Discov; 2018 Apr; 8(4):478-497. PubMed ID: 29431698
[TBL] [Abstract][Full Text] [Related]
17. Stabilization of NF-κB-Inducing Kinase Suppresses MLL-AF9-Induced Acute Myeloid Leukemia.
Xiu Y; Dong Q; Li Q; Li F; Borcherding N; Zhang W; Boyce B; Xue HH; Zhao C
Cell Rep; 2018 Jan; 22(2):350-358. PubMed ID: 29320732
[TBL] [Abstract][Full Text] [Related]
18. LSD1 inhibition exerts its antileukemic effect by recommissioning PU.1- and C/EBPα-dependent enhancers in AML.
Cusan M; Cai SF; Mohammad HP; Krivtsov A; Chramiec A; Loizou E; Witkin MD; Smitheman KN; Tenen DG; Ye M; Will B; Steidl U; Kruger RG; Levine RL; Rienhoff HY; Koche RP; Armstrong SA
Blood; 2018 Apr; 131(15):1730-1742. PubMed ID: 29453291
[TBL] [Abstract][Full Text] [Related]
19. Targeting histone methyltransferase and demethylase in acute myeloid leukemia therapy.
Castelli G; Pelosi E; Testa U
Onco Targets Ther; 2018; 11():131-155. PubMed ID: 29343972
[TBL] [Abstract][Full Text] [Related]
20. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition.
McKenney AS; Lau AN; Somasundara AVH; Spitzer B; Intlekofer AM; Ahn J; Shank K; Rapaport FT; Patel MA; Papalexi E; Shih AH; Chiu A; Freinkman E; Akbay EA; Steadman M; Nagaraja R; Yen K; Teruya-Feldstein J; Wong KK; Rampal R; Vander Heiden MG; Thompson CB; Levine RL
J Clin Invest; 2018 Feb; 128(2):789-804. PubMed ID: 29355841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
